Targeting MYC dependence in cancer by inhibiting BET bromodomains
暂无分享,去创建一个
P. Sandy | R. Sims | Deanna A. Mele | J. Mertz | L. Bergeron | A. Conery | Barbara Bryant | S. Balasubramanian
[1] C. Hsiao,et al. NUT Midline Carcinoma , 2011, International journal of surgical pathology.
[2] C. Rice,et al. Suppression of inflammation by a synthetic histone mimic , 2010, Nature.
[3] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[4] Clifford A. Meyer,et al. MYC regulation of a “poor-prognosis” metastatic cancer cell state , 2010, Proceedings of the National Academy of Sciences.
[5] M. Henriksson,et al. MYC in oncogenesis and as a target for cancer therapies. , 2010, Advances in cancer research.
[6] K. Ozato,et al. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. , 2009, Molecular biology of the cell.
[7] M. Karin,et al. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .
[8] Michael Karin,et al. Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.
[9] R. Eisenman,et al. Myc's broad reach. , 2008, Genes & development.
[10] L. Staudt,et al. IRF4 addiction in multiple myeloma , 2008, Nature.
[11] P. L. Bergsagel,et al. Characterization of MYC translocations in multiple myeloma cell lines. , 2008, Journal of the National Cancer Institute. Monographs.
[12] S. J. Flint,et al. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. , 2008, Molecular cell.
[13] M. Caligiuri,et al. A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents , 2008, Clinical Cancer Research.
[14] A. Joe,et al. Oncogene addiction. , 2008, Cancer research.
[15] Qiang Zhou,et al. Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression , 2007, Molecular and Cellular Biology.
[16] Shwu‐Yuan Wu,et al. The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation* , 2007, Journal of Biological Chemistry.
[17] M. Henriksson,et al. The Myc oncoprotein as a therapeutic target for human cancer. , 2006, Seminars in cancer biology.
[18] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] Danny Reinberg,et al. Elongation by RNA polymerase II: the short and long of it. , 2004, Genes & development.
[20] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[21] M. Eilers,et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. , 2002, Molecular cell.
[22] J. Massagué,et al. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. , 2002, Nature.
[23] C. Dang,et al. Translocations involving c-myc and c-myc function , 2001, Oncogene.